FogPharma Information

FogPharma is developing a new class of drugs to address the limitations of today’s precision medicines and achieve universal druggability. The company is pioneering the discovery, development and commercialization of HeliconTM peptides, a new drug modality that uniquely combines the broad targeting power of monoclonal antibodies with the cell-penetrating ability of small molecules. HeliconTM peptides hold the promise, not only to drug nearly all human disease drivers, but also to do so with unrivaled speed and scalability. Important Notice to Prospective Candidates: Please be aware of fraudulent recruiters who may claim to be affiliated with FogPharma. All authentic communications on behalf of Fog will come either through the Greenhouse platform or from email addresses ending in @fogpharma.com; we do not communicate with job applicants using LinkedIn messenger. Be cautious and refrain from providing personal details to any individual whose affiliation to Fog cannot be verified by the means above.